https://news.ltn.com.tw/news/world/breakingnews/3584349

治療武肺重症生力軍!美FDA緊急授權羅式關節炎藥物 - 國際 - 自由時報電子報

美國食品藥物管理局(FDA)緊急授權羅式藥廠(Roche)的類風濕性關節炎藥物安挺樂(Actemra,又稱tocilizumab),用來治療武漢肺炎(新型冠狀病毒病,COVID-19)重症患者。據《福斯新聞》報導,在針對4116名武肺重症病患的臨床試驗顯示,治療組在28天後的死亡率為30.7%,接受一般治療方式的則是34.9%。

https://news.ltn.com.tw/news/world/breakingnews/3584349
Past 31 days
Total Visit: 0
There are 0 fact-checking replies to the message
No response has been written yet. It is recommended to maintain a healthy skepticism towards it.
Add Cofacts as friend in LINE
Add Cofacts as friend in LINE
LINE 機器人
查謠言詐騙